Scil Technology GmbH

Nanohale, a German firm developing new formulations of protein and peptide therapeutics, has acquired the R&D and contract development and manufacturing services assets of Scil Technology, bringing th

Elsevier’s Strategic Transactions

Sanofi has exclusively licensed Scil Technology's preclinical stage programme for a regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, privately held Scil of German

Scil Technology, the German protein drug development and formulation company, has appointed Christian Nafe, currently CFO of the company, to CEO. Mr Nafe succeeds Dr. Weishui Weiser, who retires after